« Return to News | CROs/Service Providers

MDS Pharma Profits Sink in 3rd Quarter

Thursday, September 4, 2008 01:33 PM

Canadian life science company MDS, the parent company of King of Prussia, Pa.-based CRO MDS Pharma Services, reduced its fiscal 2008 revenue and profit outlook after reporting lower than expected third-quarter results in its contract research division. The company now expects fiscal 2008 revenue to be in the range of $1.23 billion to $1.25 billion, down from its previous forecast of $1.25 billion to $1.29 billion.

Although third quarter revenues for MDS Pharma grew 3%, to $122 million, compared with the same quarter last year, the CRO experienced a $2-million EBITDA loss compared to a $4 million gain in 2007. The decrease reflects slower than expected revenue growth in late-stage business and higher than expected costs, MDS President and CEO Stephen DeFalco told investors in a conference call today. Early stage research revenue grew but late-stage revenue decreased due to cancelled and delayed new projects.

“I’m not happy with where Pharma Services is right now and I think that’s clear,” DeFalco said.

He expressed optimism about the future based on a record $486-million backlog. “Our priority is to translate those new business wins into top and bottom line growth,” DeFalco said. 

Earlier this month, MDS Pharma appointed Ross Tonkens, MD, vice president, medical affairs, to provide medical oversight for its phase IIa clinical research activities and to direct the medical and clinical activities of MDS Pharma’s Development & Regulatory Services line of business. In June, MDS cut 210 employees, 75% of whom came from MDS Pharma.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.